Hugh Barton, Ph.D.
University of North Carolina at Chapel Hill
Dr. Hugh A. Barton is Adjunct Professor at the University of North Carolina Chapel Hill. His focus in drug discovery has been on the application of systems pharmacology and toxicology modeling, physiologically based pharmacokinetic (PBPK) modeling, and pharmacokinetic pharmacodynamic (PKPD) modeling to oncology, cardiovascular and metabolic disease, and neurodegenerative diseases. He has more than 20 years’ experience in biological modeling, including nine years with the US EPA, developing computational models for use in biologically based dose-response analyses for chemical risk assessment. In addition to positions in government and industry, Dr. Barton has been adjunct professor at Boston University School of Public Health. He received a BS in Life Sciences from the Massachusetts Institute of Technology, Cambridge, MA in 1982 and a PhD in Toxicology from the Department of Applied Biological Sciences at MIT in 1988 working with Dr. Michael A. Marletta. Dr. Barton is Past-President of the Risk Assessment Specialty Section of the Society of Toxicology, and previously was President of the Biological Modeling Specialty Section. He has served as an invited peer reviewer for Health Canada, NIEHS, US EPA, and TERA. He is a member of the US EPA Science Advisory Board’s Chemical Assessment Advisory Committee, the NRC Committee on Inorganic Arsenic, and previously he served on the WHO IPCS PBPK Modeling Working Group. He is a reviewer for numerous scientific journals and serves on two editorial boards. Dr. Barton has published more than 50 articles in the scientific literature on physiologically based pharmacokinetic and pharmacodynamic modeling and received awards from US EPA and others for that work and its applications in pharmaceutical safety and risk assessment.